PREVALENCE AND MANAGEMENT OF PANCREATIC CYSTIC NEOPLASM: A RETROSPECTIVE STUDY OVER FIVE YEARS | ||||
| ALEXMED ePosters | ||||
| Article 41, Volume 2, Issue 2, October 2020, Page 73-73 | ||||
| Document Type: Preliminary preprint short reports of original research | ||||
| DOI: 10.21608/alexpo.2020.53070.1083 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mwanabaraka Saleh Haji 
| ||||
| Department of Surgery, Faculty of Medicine, Alexandria University, Egypt | ||||
| Abstract | ||||
| • Pancreatic cystic neoplasms (PCNs) are rare disease of the pancreas accounting for 1-2% of all pancreatic tumors and 10-15% of all pancreatic lesions (PLSs). The WHO classified PCNs into benign cystic lesions (serous cystadenoma), premalignant lesions (mucinous cysts) and malignant lesions (PCNS with invasive carcinoma). • Studies reported the most common PCNs were intraductal papillary mucinous neoplasm (IPMNs), serous cystic neoplasm (SCN), mucinous cystic neoplasm (MCN), cystic pancreatic neuroendocrine tumor (CPNET) and solid pseudopapillary neoplasm (SPEN) with decreasing order frequency. The IPMN, MCN, CPNET and SPEN represent 90% of the premalignant pancreatic primary tumor. • With the increase in the utilization of the diagnostic abdominal imaging techniques, PCNs have increasingly been incidentally diagnosed. Since PCNs have varying presentations, imaging findings and malignancy potentials, studies are needed for accurate characterization of the PCNs and possible development of furthers management guidelines/protocols so that not to over treat or under treat the patients. | ||||
| Keywords | ||||
| Intraductal Papillary Mucinous Neoplasm; Pancreatic Cystic Neoplasms PCNs; Solid Pseudopapillary Neoplasm (SPEN) | ||||
|
Statistics Article View: 103 |
||||
